Reimbursed Care Access in Somalia

Currently classified as a strictly controlled substance under Somalia’s narcotics legislation with no authorized medical use outside of approved clinical research. Somalia’s drug control framework is governed by Act No. 46 (1970) and enforced by national counter‑narcotics authorities and the Attorney General’s Narcotics and Dangerous Drugs Unit, and there are no publicly available national approvals, reimbursement pathways, or sanctioned medical programs for psilocybin. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of MDMA being licensed, prescribed, or reimbursed for therapeutic use in Somalia; enforcement and prosecution of trafficking/possession are handled by Somali counter‑narcotics authorities in partnership with international agencies. # #

Esketamine (the S‑enantiomer nasal spray approved in some jurisdictions for treatment‑resistant depression) is not listed in publicly available Somali regulatory or essential‑medicines documentation and there is no evidence of national registration, authorized clinical programs, or public reimbursement for esketamine in Somalia. Somalia’s existing legal framework for narcotics and medicinal controls (Act No. 46) and the responsibilities described by the Attorney General’s narcotics unit govern any controlled‑substance authorizations, and international partners (UNODC) support law‑enforcement capacity rather than pharmaceutical reimbursement programs; access to esketamine would therefore require special import/regulatory permissions or participation in an international clinical trial, neither of which appears to be publicly documented. # #

Ketamine is explicitly present on Somalia’s essential medicines listing and is used within the health system primarily as an anesthetic/analgesic for surgical and emergency care; the 2003 Somali Essential Drugs List includes ketamine injection, indicating recognized medicinal use in clinical settings. Availability is operationally managed through public health supply chains and humanitarian health programs (including projects addressing anesthesia shortages in crisis‑affected neighbouring regions), rather than through a formal national psychiatry‑focused reimbursement program for psychedelic or psychotherapeutic indications. Regulatory oversight of narcotics in Somalia is derived from Act No. 46 (1970), and the Attorney General’s Narcotics and Dangerous Drugs Unit and the Somali Police Force’s Counter‑Narcotics Department are the principal enforcement bodies; reimbursement for ketamine‑based care in Somalia is therefore largely delivered as part of clinical service provision (hospital procurement, donor/humanitarian program supply) rather than through an insurance reimbursement mechanism akin to systems in higher‑income countries. # # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no indication of regulated therapeutic programs, licensing, or reimbursement for DMT in Somalia; enforcement is undertaken by national counter‑narcotics bodies supported by international partners. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no documented national approvals, clinical programs, or reimbursement mechanisms for 5‑MeO‑DMT in Somalia; access would be limited to tightly regulated research contexts if permitted. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of licensed ibogaine treatment centers, regulatory approval, or reimbursement in Somalia. #

Currently classified as a strictly controlled substance under national drug scheduling laws (ayahuasca preparations containing DMT are treated as controlled), with no authorized medical use outside of approved clinical research. There is no evidence of lawful ritual exemptions, regulated sacramental access, or reimbursement schemes in Somalia. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no documented approvals, therapeutic programs, or reimbursement for mescaline in Somalia. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel synthetic phenethylamines (the '2C‑x' family) are not authorized for medical use in Somalia and are subject to counter‑narcotics enforcement; there are no public reimbursement pathways or licensed therapeutic programs. #